Tag: ESC
Renal Interventions’ top 10 stories of October 2024
October brought with it one-year trial outcomes, technique recommendations, and meeting updates, with Venova Medical presenting one-year results from the VENOS-1 first-in-human (FIH) trial,...
Pooled analysis of over 18,000 participants supports benefits of finerenone across...
A pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events...